LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 322

Search options

  1. Article ; Online: Alzheimer's disease - the 'microbial hypothesis' from a clinical and neuroimaging perspective.

    Frölich, Lutz

    Psychiatry research. Neuroimaging

    2020  Volume 306, Page(s) 111181

    Abstract: The etiology of Alzheimer's disease (AD) is under debate since its first description in 1906. Extracellular senile plaques composed of beta-amyloid peptide (Aβ) and intracellular neurofibrillary tangles composed of tau protein characterize the ... ...

    Abstract The etiology of Alzheimer's disease (AD) is under debate since its first description in 1906. Extracellular senile plaques composed of beta-amyloid peptide (Aβ) and intracellular neurofibrillary tangles composed of tau protein characterize the histopathology of the disease. The 'amyloid cascade hypothesis' summarizes the molecular mechanisms leading to deposition of these proteins. However, treatments derived from this hypothesis have been unsuccessful. An infectious etiology for AD has been repeatedly proposed. Neurotropic viruses, gut and lung bacteriae, and Bovine Meat and Milk Factors have been implicated in neurodegenerative disorders including AD. These pathogens may act directly or as a trigger or co-factor for inducing neurodegeneration in AD. The antimicrobial properties of beta-amyloid have shifted the discussion of the etiological origin of AD towards an interaction hypothesis. Neuroimaging studies have added to the understanding of mechanisms involved in neurodegeneration. Antiviral agents and a bacterial protease inhibitor targeting Porphyromonas gingivalis toxins are currently tested in clinical trials. Further clinical studies are needed to test if strategies directly derived from the 'microbial hypothesis' or combination strategies including antimicrobial agents may be beneficial for patients with Alzheimer's disease.
    MeSH term(s) Alzheimer Disease/diagnostic imaging ; Alzheimer Disease/etiology ; Alzheimer Disease/microbiology ; Alzheimer Disease/pathology ; Amyloid beta-Peptides ; Animals ; Cattle ; Humans ; Neuroimaging ; tau Proteins
    Chemical Substances Amyloid beta-Peptides ; tau Proteins
    Language English
    Publishing date 2020-09-04
    Publishing country Netherlands
    Document type Journal Article ; Review
    ZDB-ID 445361-x
    ISSN 1872-7506 ; 1872-7123 ; 0925-4927 ; 0165-1781
    ISSN (online) 1872-7506 ; 1872-7123
    ISSN 0925-4927 ; 0165-1781
    DOI 10.1016/j.pscychresns.2020.111181
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1541: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: Erratum zu: Krankheitsmodifizierende Therapieansätze bei Alzheimer-Krankheit.

    Frölich, Lutz / Hausner, Lucrezia

    Der Nervenarzt

    2022  

    Title translation Erratum to: Disease-modifying treatment approaches for Alzheimer's disease.
    Language German
    Publishing date 2022-08-12
    Publishing country Germany
    Document type Published Erratum
    ZDB-ID 123291-5
    ISSN 1433-0407 ; 0028-2804
    ISSN (online) 1433-0407
    ISSN 0028-2804
    DOI 10.1007/s00115-022-01366-3
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Ui II Zs.100: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 446: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Book: Patientenrelevante Endpunkte bei der Behandlung von Demenzkranken

    Füsgen, Ingo / Frölich, Lutz

    17. Juni 2005 in Frankfurt

    (Dokumentationsband / Zukunftsforum Demenz ; 14 ; ... Workshop des "Zukunftsforum Demenz" ; 18)

    2005  

    Institution Zukunftsforum Demenz
    Author's details Zukunftsforum Demenz. Herausgeber Ingo Füsgen ; Lutz Frölich
    Series title Dokumentationsband / Zukunftsforum Demenz ; 14
    ... Workshop des "Zukunftsforum Demenz" ; 18
    Dokumentationsband
    ... Workshop des "Zukunftsforums Demenz"
    Collection Dokumentationsband
    ... Workshop des "Zukunftsforums Demenz"
    Keywords Alzheimerkrankheit
    Subject Alzheimer-Krankheit ; Alzheimersche Krankheit ; Alzheimer-Demenz ; Morbus Alzheimer ; Greisenblödsinn ; Alzheimer's Disease
    Language German
    Size 59 Seiten, Illustrationen, Diagramme, 21 cm, 140 gr.
    Publisher Medical-Tribune-Verlagsgesellschaft
    Publishing place Wiesbaden
    Publishing country Germany
    Document type Book
    HBZ-ID HT016132226
    ISBN 3-938748-00-1 ; 978-3-938748-00-8
    Database Catalogue ZB MED Medicine, Health

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Shelf markLoan statusLocation
    2009 A 5512 order for loan Magazin

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Book ; Conference proceedings: Innovative Therapieansätze - in welche Richtung geht die Alzheimer-Therapie?

    Füsgen, Ingo / Frölich, Lutz

    14. Workshop des "Zukunftsforum Demenz", 14./15. Mai 2004 in Schlangenbad

    (Dokumentationsband / Zukunftsforum Demenz ; 10 ; ... Workshop des "Zukunftsforum Demenz" ; 14)

    2004  

    Institution Zukunftsforum Demenz
    Author's details Herausgeber Ingo Füsgen, Lutz Frölich
    Series title Dokumentationsband / Zukunftsforum Demenz ; 10
    ... Workshop des "Zukunftsforum Demenz" ; 14
    Dokumentationsband
    ... Workshop des "Zukunftsforums Demenz"
    Collection Dokumentationsband
    ... Workshop des "Zukunftsforums Demenz"
    Keywords Alzheimerkrankheit ; Pharmakotherapie
    Subject Arzneimitteltherapie ; Arzneitherapie ; Medikamentöse Therapie ; Alzheimer-Krankheit ; Alzheimersche Krankheit ; Alzheimer-Demenz ; Morbus Alzheimer ; Greisenblödsinn ; Alzheimer's Disease
    Language German
    Size 68 Seiten, Illustrationen, Diagramme
    Publisher Medical-Tribune-Verlagsgesellschaft
    Publishing place Wiesbaden
    Publishing country Germany
    Document type Book ; Conference proceedings
    HBZ-ID HT014547977
    ISBN 3-922264-75-1 ; 978-3-922264-75-0
    Database Catalogue ZB MED Medicine, Health

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Shelf markLoan statusLocation
    2005 A 4959 order for loan Magazin

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article ; Online: Krankheitsmodifizierende Therapieansätze bei Alzheimer-Krankheit.

    Frölich, Lutz / Hausner, Lucrezia

    Der Nervenarzt

    2021  Volume 92, Issue 12, Page(s) 1239–1248

    Abstract: Alzheimer's disease is one the major common diseases but so far only with symptomatic treatment options. New insights define the disease as a slowly progressive continuum with very long preclinical and early symptomatic phases. Innovative molecular ... ...

    Title translation Disease-modifying treatment approaches for Alzheimer's disease.
    Abstract Alzheimer's disease is one the major common diseases but so far only with symptomatic treatment options. New insights define the disease as a slowly progressive continuum with very long preclinical and early symptomatic phases. Innovative molecular treatment strategies are based on an improved understanding of the molecular neurobiology of the disease, opening up a variety of therapeutic targets. For the first time, an anti-amyloid antibody has been approved in the USA in 2021 as a disease-modifying treatment for Alzheimer's disease, representing a first highly controversial step towards a molecular, cause-oriented treatment. This review presents the most advanced molecular treatment strategies and discusses the implications of the approved antibody treatment for the clinical practice. The special features of this long-term treatment with i.v. infusions in a particularly vulnerable population and a special side effect profile will impose significant challenges for implementation in the practice and will require a high degree of cooperation within the healthcare system. The future of Alzheimer's treatment with a multimodal therapeutic approach with different classes of drugs will probably reinforce these trends.
    MeSH term(s) Alzheimer Disease/diagnosis ; Alzheimer Disease/drug therapy ; Amyloid beta-Peptides ; Humans ; tau Proteins
    Chemical Substances Amyloid beta-Peptides ; tau Proteins
    Language German
    Publishing date 2021-11-04
    Publishing country Germany
    Document type Journal Article ; Review
    ZDB-ID 123291-5
    ISSN 1433-0407 ; 0028-2804
    ISSN (online) 1433-0407
    ISSN 0028-2804
    DOI 10.1007/s00115-021-01222-w
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Ui II Zs.100: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 446: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  6. Article ; Online: Large Collaborative Registries and Real-world Data to Manage Amyloid-Related Imaging Abnormalities.

    Piazza, Fabrizio / Frölich, Lutz / Padovani, Alessandro

    JAMA neurology

    2022  Volume 79, Issue 6, Page(s) 633–634

    MeSH term(s) Amyloidogenic Proteins ; Amyloidosis ; Humans ; Registries
    Chemical Substances Amyloidogenic Proteins
    Language English
    Publishing date 2022-04-25
    Publishing country United States
    Document type Journal Article ; Comment
    ZDB-ID 2702023-X
    ISSN 2168-6157 ; 2168-6149
    ISSN (online) 2168-6157
    ISSN 2168-6149
    DOI 10.1001/jamaneurol.2022.0731
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Ui II Zs.191: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  7. Article: Aducanumab - Aduhelm®: Einsatz nach negativem Votum der EMA?

    Fritze, Jürgen / Frölich, Lutz

    Psychopharmakotherapie

    2022  Volume 29, Issue 2, Page(s) 64

    Language German
    Document type Article
    ZDB-ID 1196510-1
    ISSN 0944-6877
    Database Current Contents Medicine

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 4299: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  8. Article: Aducanumab - Aduhelm®: Einsatz nach negativem Votum der EMA? Addendum: Biogen hat Zulassungsantrag zurückgezogen

    Fritze, Jürgen / Frölich, Lutz

    Psychopharmakotherapie

    2022  Volume 29, Issue 3, Page(s) 106

    Language German
    Document type Article
    ZDB-ID 1196510-1
    ISSN 0944-6877
    Database Current Contents Medicine

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 4299: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  9. Article ; Online: Medikamentöse Therapie der Alzheimer-Demenz mit Antidementiva.

    Hausner, Lucrezia / Frölich, Lutz

    Deutsche medizinische Wochenschrift (1946)

    2019  Volume 144, Issue 3, Page(s) 156–160

    Abstract: Antidementia therapy: The clinical use of acetylcholinesterase inhibitors (AChE-I) for the symptomatic treatment of mild to moderate Alzheimer's dementia is recognized worldwide, despite its modest effectiveness. AChE-I may be continued to be used into ... ...

    Title translation Antidementia Drug Therapy of Alzheimer's Dementia: Status 2018 and Outlook.
    Abstract Antidementia therapy: The clinical use of acetylcholinesterase inhibitors (AChE-I) for the symptomatic treatment of mild to moderate Alzheimer's dementia is recognized worldwide, despite its modest effectiveness. AChE-I may be continued to be used into severe stages of the dementia. In moderate to severe Alzheimer's dementia, the NMDA-receptor-antagonist Memantin is indicated.Lewy body dementia is treated as Alzheimer's disease; for Parkinson's dementia, there is a separate indication for rivastigmin. A worsening in motor symptoms may occur. There is no evidence-based antidementia drug therapy for frontotemporal or vascular dementia.Future Therapeutic Strategies: Disease modification is a major focus of current clinical trials. There are several clinical trials targeting anti-amyloid (phase 3) or anti-tau strategies. However, other therapeutic targets are persued, too. In current clinical trials, mild cognitive impairment due to Alzheimer's disease is targeted as the most meaningful study population.Implications for practice: At present, there just is symptomatic anti-dementive drug therapy available for Alzheimer's dementia, Parkinson's dementia and Lewy body dementia. Despite its modest effect sizes, treatment with these drugs is clinically relevant and seems to be cost-effective.
    MeSH term(s) Alzheimer Disease/drug therapy ; Cholinesterase Inhibitors/therapeutic use ; Dementia, Vascular/drug therapy ; Humans ; Lewy Body Disease/drug therapy ; Memantine/therapeutic use
    Chemical Substances Cholinesterase Inhibitors ; Memantine (W8O17SJF3T)
    Language German
    Publishing date 2019-01-31
    Publishing country Germany
    Document type Journal Article
    ZDB-ID 200446-x
    ISSN 1439-4413 ; 0012-0472
    ISSN (online) 1439-4413
    ISSN 0012-0472
    DOI 10.1055/a-0658-6720
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Ua VI Zs.60: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)
    Ua VI Zs.60/X: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  10. Article ; Online: Die „vierte Welle“? COVID-19 und konsekutive kognitive Störungen.

    Berlit, Peter / Frölich, Lutz / Förstl, Hans

    Deutsche medizinische Wochenschrift (1946)

    2021  Volume 146, Issue 10, Page(s) 671–676

    Abstract: The COVID-19 pandemic poses new challenges for the healthcare systems world-wide which will go beyond prevention, acute and intensive care treatment of patients with severe illness. A large proportion of "COVID-survivors" - and not only elderly patients - ...

    Title translation The "Fourth Wave"? COVID-19 and consecutive cognitive impairment.
    Abstract The COVID-19 pandemic poses new challenges for the healthcare systems world-wide which will go beyond prevention, acute and intensive care treatment of patients with severe illness. A large proportion of "COVID-survivors" - and not only elderly patients - suffers from "post-COVID-syndrome". Risk factors are preexisting somatic multimorbidity, cognitive and cerebral changes together with pneumonia and hypoxemia, intensive care treatment and confusional states during the acute phase of illness. Post-COVID cognitive deficits usually manifest as a frontal dysexecutive syndrome combined with fatigue and dysphoria and/or with attentional and memory deficits. Several pathogenetic mechanisms of COVID encephalopathy are understood, but no specific treatment strategies have been established so far. We assume that general practitioners, psychiatrists, neurologists and social workers will need to take care of the activation, reintegration and expert appraisals of patients with post-COVID fatigue and cognitive deficits during the years to come.
    MeSH term(s) Aged ; COVID-19/complications ; COVID-19/epidemiology ; COVID-19/physiopathology ; Cognitive Dysfunction/epidemiology ; Cognitive Dysfunction/physiopathology ; Cognitive Dysfunction/virology ; Female ; Humans ; Male ; Middle Aged ; Multimorbidity ; Pandemics ; Risk Factors ; SARS-CoV-2
    Language German
    Publishing date 2021-05-06
    Publishing country Germany
    Document type Journal Article
    ZDB-ID 200446-x
    ISSN 1439-4413 ; 0012-0472
    ISSN (online) 1439-4413
    ISSN 0012-0472
    DOI 10.1055/a-1468-1529
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Ua VI Zs.60: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)
    Ua VI Zs.60/X: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top